ArticleMedicina (Kaunas, Lithuania)2025
Impact of Treatment Duration in First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Multicenter Real-World Retrospective Study.
Mehmet Nuri Baser, Bilgin Demir, Gamze Serin Ozel, Gamze Gokoz Dogu, Serdar Karakaya, Mucahit Ugar, Naziye Ak, Ahmet Ozveren, Ufuk Camanlı, Olcun Umit Unal and 2 more
Abstract readMulticenter Study
In one paragraphArticle in Medicina (Kaunas, Lithuania), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Mehmet Nuri BaserDepartment of Medical Oncology, Faculty of Medicine, Adnan Menderes University, Aydin 09010, Turkey.ORCID 0000-0003-1809-5581 Bilgin DemirDepartment of Medical Oncology, Faculty of Medicine, Adnan Menderes University, Aydin 09010, Turkey.
Gamze Serin OzelDepartment of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli 20160, Turkey.ORCID 0009-0002-3631-6771 Gamze Gokoz DoguDepartment of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli 20160, Turkey.ORCID 0000-0001-8142-0362 Serdar KarakayaDepartment of Medical Oncology, Atatürk Sanatoryum Training and Research Hospital, Ankara 06290, Turkey.ORCID 0000-0002-2111-7131 Mucahit UgarDepartment of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul 34093, Turkey.
Naziye AkDepartment of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul 34093, Turkey.ORCID 0000-0001-5790-7066 Ahmet OzverenDepartment of Medical Oncology, Acıbadem Kent Hospital, Izmir 35630, Turkey.
Ufuk CamanlıDepartment of Medical Oncology, Izmir City Hospital, Izmir 35540, Turkey.
Olcun Umit UnalDepartment of Medical Oncology, Izmir City Hospital, Izmir 35540, Turkey.
Merve TuranDepartment of Medical Oncology, Faculty of Medicine, Adnan Menderes University, Aydin 09010, Turkey.
Esin OktayDepartment of Medical Oncology, Faculty of Medicine, Adnan Menderes University, Aydin 09010, Turkey.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsDuration of TherapyLung NeoplasmsSmall Cell Lung CarcinomaAdultAgedAged, 80 and overAntineoplastic AgentsFemaleHumansMaleMiddle AgedRetrospective StudiesTime FactorsTurkeyAntibodies, Monoclonal, HumanizedAntineoplastic Agentsatezolizumabchemotherapyimmunotherapysmall-cell lung cancer
Identifiers
PMID40731859
PMCPMC12298966
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390